Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zetomipzomib in active lupus nephritis
NCT05781750Phase 2Terminated
- Sponsor
- Kezar Life Sciences
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of zetomipzomib in lupus nephritis (LN) (3 arms), sponsored by Kezar Life Sciences. Primary endpoint: Complete Renal Response at 37 weeks. Started Nov 2023; status: terminated.
02
Drugs
zetomipzomib
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT05781750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05781750.